LifeArc launched bold new strategy for their Childhood Cancer Translational Challenge
Marc Ramis Castelltort, Managing Partner at Montana Impact Fund, shared a post by LifeArc on LinkedIn, adding:
“A very special atmosphere yesterday in London at the presentation of the Childhood Cancer Translation Challenge.
It is the leading cause of disease-related death in children over 5 globally. Also, 95% Childhood Cancer survivors have significant health issues by 45 years old.
This amazing initiative aims to bridge the gaps in childhood cancer translational research.”
Quoting LifeArc‘s post:
“We believe we can do better for children with cancer. Yesterday, we officially launched our bold new strategy for our Childhood Cancer Translational Challenge.
Our aim is to catalyse a paradigm shift in how we understand, diagnose and treat childhood cancers. To do this, we are focussing on 3 key priorities:
1.Better treatments: Developing therapies specifically targeted to the unique biology of childhood cancers.
2.Better trials: Improving the way clinical trials are run to help make sure the most promising new treatments get to the children who need them more quickly.
3.Better decisions: Using advanced biomarkers to guide clinicians to make informed decisions at diagnosis and throughout treatment.
Source: Marc Ramis Castelltort/LinkedIn and LifeArc/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023